이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PW Medtech Group 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yue'e Zhang

최고 경영자

CN¥1.1m

총 보상

CEO 급여 비율	100.0%
CEO 임기	5.5yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4.7yrs
이사회 평균 재임 기간	11.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Yue'e Zhang 의 보수는 PW Medtech Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥152m
Mar 31 2024	n/a	n/a	CN¥153m
Dec 31 2023	CN¥1m	CN¥1m	CN¥153m
Sep 30 2023	n/a	n/a	CN¥135m
Jun 30 2023	n/a	n/a	CN¥116m
Mar 31 2023	n/a	n/a	CN¥111m
Dec 31 2022	CN¥1m	CN¥1m	CN¥106m
Sep 30 2022	n/a	n/a	CN¥72m
Jun 30 2022	n/a	n/a	CN¥39m
Mar 31 2022	n/a	n/a	CN¥389m
Dec 31 2021	CN¥1m	CN¥1m	CN¥739m
Sep 30 2021	n/a	n/a	CN¥995m
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥942m
Dec 31 2020	CN¥1m	CN¥1m	CN¥632m
Sep 30 2020	n/a	n/a	CN¥398m
Jun 30 2020	n/a	n/a	CN¥163m
Mar 31 2020	n/a	n/a	CN¥123m
Dec 31 2019	CN¥1m	CN¥1m	CN¥82m
Jun 30 2019	n/a	n/a	CN¥136m
Mar 31 2019	n/a	n/a	CN¥126m
Dec 31 2018	CN¥995k	CN¥995k	CN¥115m
Jun 30 2018	n/a	n/a	CN¥27m
Mar 31 2018	n/a	n/a	CN¥16m
Dec 31 2017	CN¥1m	CN¥1m	CN¥5m

보상 대 시장: Yue'e 의 총 보상 ($USD 146.34K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 760.26K ).

보상과 수익: Yue'e 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Yue'e Zhang (61 yo)

5.5yrs

테뉴어

CN¥1,062,000

보상

Ms. Yue'e Zhang has been Chief Executive Officer at PW Medtech Group Ltd. since March 31, 2019. Ms. Zhang serves as a General Manager, Senior Engineer and Executive Director of WP Medical Technologies, Inc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yue'e Zhang	Executive Chairman & CEO	5.5yrs	CN¥1.06m	데이터 없음
Tian Tian	Financial Director	4.7yrs	데이터 없음	데이터 없음
Ka Man So	Company Secretary	2.1yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: PWE 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yue'e Zhang	Executive Chairman & CEO	13.3yrs	CN¥1.06m	데이터 없음
Xiaogang Wang	Independent Non-Executive Director	10.9yrs	CN¥181.00k	데이터 없음
Geng Chen	Independent Non-Executive Director	10.9yrs	CN¥181.00k	0.042% CN¥ 81.8k
Liwei Jiang	Non-Executive Director	11.3yrs	CN¥300.00k	0.17% CN¥ 338.9k
Junshan Lin	Non-Executive Director	11.3yrs	CN¥300.00k	0.11% CN¥ 214.9k
Fengli Wang	Independent Non-Executive Director	3.1yrs	CN¥181.00k	데이터 없음

11.1yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: PWE 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).

PW Medtech Group 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Recent updates

First half 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.045 in 1H 2023)

Insufficient new directors

PW Medtech Group Limited to Report First Half, 2024 Results on Aug 30, 2024

Now 22% overvalued

Upcoming dividend of HK$0.05 per share

PW Medtech Group Limited (SEHK:1358) announces an Equity Buyback for HKD 150 million worth of its shares.

Now 38% overvalued after recent price rise

Now 25% overvalued after recent price rise

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Upcoming dividend of HK$0.049 per share at 11% yield

First half 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.039 in 1H 2022)

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings released: EPS: CN¥0.47 (vs CN¥0.40 in FY 2020)

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings released: EPS: CN¥0.47 (vs CN¥0.40 in FY 2020)

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Independent Non-Executive Director Xingdong Zhang has left the company

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

New 90-day high: €0.21

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령